WO2007001487A3 - Modulation of negative immune regulators and applications for immunotherapy - Google Patents

Modulation of negative immune regulators and applications for immunotherapy Download PDF

Info

Publication number
WO2007001487A3
WO2007001487A3 PCT/US2006/001751 US2006001751W WO2007001487A3 WO 2007001487 A3 WO2007001487 A3 WO 2007001487A3 US 2006001751 W US2006001751 W US 2006001751W WO 2007001487 A3 WO2007001487 A3 WO 2007001487A3
Authority
WO
WIPO (PCT)
Prior art keywords
negative immune
immunotherapy
modulation
applications
immune regulators
Prior art date
Application number
PCT/US2006/001751
Other languages
French (fr)
Other versions
WO2007001487A2 (en
Inventor
Si-Yi Chen
Kevin C Evel-Kabler
Xiaotong Song
Xue F Huang
Andrew Sharabi
Original Assignee
Baylor College Medicine
Si-Yi Chen
Kevin C Evel-Kabler
Xiaotong Song
Xue F Huang
Andrew Sharabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/022396 external-priority patent/WO2006112869A2/en
Application filed by Baylor College Medicine, Si-Yi Chen, Kevin C Evel-Kabler, Xiaotong Song, Xue F Huang, Andrew Sharabi filed Critical Baylor College Medicine
Priority to JP2008518123A priority Critical patent/JP2008546775A/en
Priority to CA002613166A priority patent/CA2613166A1/en
Priority to EP06718772A priority patent/EP1917038A4/en
Priority to AU2006262917A priority patent/AU2006262917A1/en
Priority to KR1020087001727A priority patent/KR20080052549A/en
Priority to CN200680030689.6A priority patent/CN101501055B/en
Publication of WO2007001487A2 publication Critical patent/WO2007001487A2/en
Publication of WO2007001487A3 publication Critical patent/WO2007001487A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Abstract

The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism to break self tolerance in tumor vaccination methods that rely on presentation of self tumor antigens.
PCT/US2006/001751 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy WO2007001487A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008518123A JP2008546775A (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and application for immunotherapy
CA002613166A CA2613166A1 (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy
EP06718772A EP1917038A4 (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy
AU2006262917A AU2006262917A1 (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy
KR1020087001727A KR20080052549A (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy
CN200680030689.6A CN101501055B (en) 2005-06-23 2006-01-19 The adjusting of negativity immune-regulating factor and immunotherapy application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US05/22396 2005-06-23
PCT/US2005/022396 WO2006112869A2 (en) 2004-07-19 2005-06-23 Modulation of cytokine signaling regulators and applications for immunotherapy

Publications (2)

Publication Number Publication Date
WO2007001487A2 WO2007001487A2 (en) 2007-01-04
WO2007001487A3 true WO2007001487A3 (en) 2009-04-23

Family

ID=37595624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001751 WO2007001487A2 (en) 2005-06-23 2006-01-19 Modulation of negative immune regulators and applications for immunotherapy

Country Status (6)

Country Link
EP (1) EP1917038A4 (en)
JP (1) JP2008546775A (en)
KR (1) KR20080052549A (en)
AU (1) AU2006262917A1 (en)
CA (1) CA2613166A1 (en)
WO (1) WO2007001487A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175735A1 (en) * 2011-06-23 2012-12-27 Vib Vzw A20 inhibitors for the treatment of respiratory viral infections
CN104830786A (en) * 2015-05-05 2015-08-12 杨光华 DC cell based on HER-2/NEU antigen, targeting immune cell population, preparation method and applications thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US20030013841A1 (en) * 2001-03-01 2003-01-16 Takeshi Imamura Novel polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner
US20030171253A1 (en) * 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US20030013841A1 (en) * 2001-03-01 2003-01-16 Takeshi Imamura Novel polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner
US20030171253A1 (en) * 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUMMELKAMP ET AL.: "Stable Suppression of tumorigenicity by virus-mediated RNA interference.", CANCER CELL., vol. 2, September 2002 (2002-09-01), pages 243 - 247, XP009006464 *
HEYNINCK ET AL.: "A20 inhibits NF kappa B activation by dual ubiquitin-editing functions.", TRENDS BIOCHEM SCI., vol. 1, January 2005 (2005-01-01), pages 1 - 4, XP008125720 *
SCHMIDT ET AL.: "Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.", BLOOD., vol. 102, July 2003 (2003-07-01), pages 571 - 576, XP002283858 *
YAMAMOTO ET AL.: "SOCS-3 inhibits IL-12 induced STAT4 activation by binding through its SH2 domain to the STAT4 deocking site in the IL-12 receptor beta2 subunit.", BIOCHEM BIOPHYS RES COMM., vol. 310, September 2003 (2003-09-01), pages 1188 - 1193, XP004464089 *

Also Published As

Publication number Publication date
WO2007001487A2 (en) 2007-01-04
EP1917038A2 (en) 2008-05-07
KR20080052549A (en) 2008-06-11
AU2006262917A1 (en) 2007-01-04
CA2613166A1 (en) 2007-01-04
JP2008546775A (en) 2008-12-25
EP1917038A4 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
WO2006112869A3 (en) Modulation of cytokine signaling regulators and applications for immunotherapy
MX2009008140A (en) Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells.
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
MX2021007556A (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells.
MX2011009438A (en) Anti-cd40 antibodies and uses thereof.
WO2010006753A3 (en) Silicon dioxide nanoparticles and their use for vaccination
MX2010008633A (en) Breaking immunological tolerance with a genetically encoded unnatural amino acid.
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
MX337397B (en) Antigen presenting cell targeted anti-viral vaccines.
BR112015000657A8 (en) use of a genetically modified cell to express a car.
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
MX2020012144A (en) Vaccine composition.
MY161170A (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2005042581A3 (en) Modified anti-cd52 antibody
WO2007071997A3 (en) Method of eliciting immune response
WO2009134429A3 (en) Methods and compositions for modulating immunological tolerance
MX2010010265A (en) Methods for treating psoriasis.
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
SG179135A1 (en) Methods for treating psoriasis
MY152175A (en) Vaccine antigen capable of inducing cross-reacting and neutralizing antibody againts high-risk-type human papillomavirus
WO2007053455A3 (en) Polypeptide ligans for toll-like receptor 4 (tlr4)
WO2012144726A3 (en) Tumor antigen proteins or genes of polo-like kinase 1
MX2020012186A (en) Peptide display to antigen presenting cells using lipid vehicle.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680030689.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006262917

Country of ref document: AU

Ref document number: 9908/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008518123

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2613166

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006718772

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087001727

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006262917

Country of ref document: AU

Date of ref document: 20060119

Kind code of ref document: A